IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Webhead who wrote (1261)	9/14/1997 4:41:00 PM
From: Benadam	of 1762

About Market Size: I wouldn't dare any figures but here are two tidbits of partial info: 1. European specialists are prepared to administer Rituxan as soon as Q4/97 for relapsed NHL, and all occurences of follicular NHL are potentially relapsing; 2. the next drug, used as a targeting device for a kind of 'smart bomb' against cancerous lymphatic nodes could become a first-line treatment, replacing the current chemiotherapy sometimes combined with radiotherapy at a much lower cost for the patient's well-being and for the health care system. 3. the number of patients with NHL seems to be increasing for unknown reasons. With this in mind, I am surprised that the FDA expected official approval is receiving so little media coverage. this should make IDEC's future rather good... Yours.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next